Amirali Talasaz Sells 143,028 Shares of Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) CEO Amirali Talasaz sold 143,028 shares of the business’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $151.54, for a total value of $21,674,463.12. Following the transaction, the chief executive officer directly owned 1,881,336 shares in the company, valued at $285,097,657.44. This trade represents a 7.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Amirali Talasaz also recently made the following trade(s):

• On Friday, June 26th, Amirali Talasaz sold 116,972 shares of Guardant Health stock. The stock was sold at an average price of $150.79, for a total value of $17,638,207.88.
• On Wednesday, May 20th, Amirali Talasaz sold 210,000 shares of Guardant Health stock. The stock was sold at an average price of $109.89, for a total value of $23,076,900.00.
• On Tuesday, May 12th, Amirali Talasaz sold 50,000 shares of Guardant Health stock. The shares were sold at an average price of $100.32, for a total transaction of $5,016,000.00.

Guardant Health Trading Up 13.8%

Shares of GH opened at $170.77 on Thursday. Guardant Health, Inc. has a 12-month low of $40.35 and a 12-month high of $172.61. The firm has a 50-day moving average price of $116.77 and a 200 day moving average price of $105.20. The firm has a market capitalization of $22.64 billion, a P/E ratio of -50.37 and a beta of 1.59.

Institutional Investors Weigh In On Guardant Health

Institutional investors have recently made changes to their positions in the stock. V Square Quantitative Management LLC acquired a new position in shares of Guardant Health in the 4th quarter worth approximately $27,000. Chesapeake Asset Management LLC acquired a new stake in Guardant Health in the 4th quarter valued at approximately $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Guardant Health in the 4th quarter valued at approximately $31,000. Elyxium Wealth LLC acquired a new stake in Guardant Health in the 4th quarter valued at approximately $35,000. Finally, Parallel Advisors LLC raised its position in Guardant Health by 164.7% in the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after purchasing an additional 219 shares during the period. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

GH has been the subject of several analyst reports. TD Cowen reissued a “buy” rating on shares of Guardant Health in a research note on Thursday, May 21st. Guggenheim lifted their price target on shares of Guardant Health from $135.00 to $160.00 and gave the company a “buy” rating in a research report on Monday. BTIG Research upped their price objective on Guardant Health from $160.00 to $190.00 and gave the company a “buy” rating in a report on Wednesday. Mizuho increased their price objective on Guardant Health from $135.00 to $175.00 and gave the stock an “outperform” rating in a research report on Monday, June 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a research note on Tuesday, April 21st. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $146.18.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.